IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Neuphoria Therapeutics Inc (NEUP)

CUSIP: 64136E102 | NYSE | Healthcare · Biotechnology | Micro Cap | 38 institutional holders

Quarters

Q3 2026Q2 2026Q1 2026Q4 2025Q3 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13GAdvisorShares Trust312,8955.8%New 5%+ stakeSep 30, 2026No 13F filer matched
13G/ACoastlands Capital LP228,5944.2%Newly reportedJul 23, 2026

Institutional Holders — Q3 2026

Barclays PLC3
0.0% of portfolio›$11
StyleTurnoverLocationFiled
Barclays PLC
3$110.0%CoreMediumLondon, United Kingdom2026-11-06
No 13F filer matched
13GAdvisorShares Trust312,895
5.8% of class · Sep 30, 2026New 5%+ stake
No 13F filer matched
13G/ACoastlands Capital LP228,594
4.2% of class · Jul 23, 2026Newly reported
No 13F filer matched